$XLO
Xilio Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000155837023014711 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.310M $6.898M
YoY Change -11.97% -16.95%
% of Gross Profit
Research & Development $11.05M $13.22M
YoY Change -15.24% -18.64%
% of Gross Profit
Depreciation & Amortization $460.0K $492.0K
YoY Change -2.75% 10.56%
% of Gross Profit
Operating Expenses $17.36M $20.12M
YoY Change -14.08% -18.07%
Operating Profit -$17.36M -$20.12M
YoY Change -14.08% -18.07%
Interest Expense -$200.0K -$100.0K
YoY Change 0.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $613.0K $761.0K
YoY Change 47.36% -1347.54%
Pretax Income -$16.75M -$19.36M
YoY Change -15.36% -21.36%
Income Tax
% Of Pretax Income
Net Earnings -$16.75M -$19.36M
YoY Change -15.37% -21.36%
Net Earnings / Revenue
Basic Earnings Per Share -$0.61 -$0.70
Diluted Earnings Per Share -$0.61 -$0.70
COMMON SHARES
Basic Shares Outstanding 27.54M 27.47M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.80M $75.38M
YoY Change -57.02% -52.71%
Cash & Equivalents $59.77M $75.40M
Short-Term Investments
Other Short-Term Assets $4.700M $3.042M
YoY Change 48.22% -15.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $64.48M $78.43M
YoY Change -54.69% -51.89%
LONG-TERM ASSETS
Property, Plant & Equipment $6.366M $6.798M
YoY Change -15.72% -8.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $169.0K $197.0K
YoY Change -43.85% -41.19%
Total Long-Term Assets $13.36M $13.93M
YoY Change -11.51% -7.84%
TOTAL ASSETS
Total Short-Term Assets $64.48M $78.43M
Total Long-Term Assets $13.36M $13.93M
Total Assets $77.84M $92.36M
YoY Change -50.55% -48.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.486M $945.0K
YoY Change -17.9% -32.98%
Accrued Expenses $9.404M $7.140M
YoY Change 3.77% -40.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $7.145M
YoY Change 0.0% 114.37%
Total Short-Term Liabilities $16.93M $16.29M
YoY Change 0.52% -8.31%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $8.400M $7.000K
YoY Change 13025.0% -91.46%
Total Long-Term Liabilities $8.400M $7.000K
YoY Change 13025.0% -91.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.93M $16.29M
Total Long-Term Liabilities $8.400M $7.000K
Total Liabilities $25.34M $24.98M
YoY Change -18.55% -26.33%
SHAREHOLDERS EQUITY
Retained Earnings -$307.9M -$291.1M
YoY Change 35.83% 40.73%
Common Stock $3.000K $3.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.50M $67.38M
YoY Change
Total Liabilities & Shareholders Equity $77.84M $92.36M
YoY Change -50.55% -48.15%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$16.75M -$19.36M
YoY Change -15.37% -21.36%
Depreciation, Depletion And Amortization $460.0K $492.0K
YoY Change -2.75% 10.56%
Cash From Operating Activities -$13.37M -$16.57M
YoY Change -32.84% -1.09%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $316.0K
YoY Change -100.0% -140.99%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$316.0K
YoY Change -100.0% -59.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.240M -992.0K
YoY Change 10081.82% 4623.81%
NET CHANGE
Cash From Operating Activities -13.37M -16.57M
Cash From Investing Activities 0.000 -316.0K
Cash From Financing Activities -2.240M -992.0K
Net Change In Cash -15.61M -17.88M
YoY Change -22.97% 1.9%
FREE CASH FLOW
Cash From Operating Activities -$13.37M -$16.57M
Capital Expenditures $0.00 $316.0K
Free Cash Flow -$13.37M -$16.89M
YoY Change -31.7% 5.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Central Index Key
EntityCentralIndexKey
0001840233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40925
dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
524-2466
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
XLO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27539620
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75383000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120385000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3042000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4111000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
78425000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
124496000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1574000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1562000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6798000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5365000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5585000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
197000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
267000
CY2023Q2 us-gaap Assets
Assets
92359000
CY2022Q4 us-gaap Assets
Assets
139165000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
945000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3125000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7140000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
981000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
918000
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
7145000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
6667000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16293000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21119000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3165000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8682000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45000
CY2023Q2 us-gaap Liabilities
Liabilities
24982000
CY2022Q4 us-gaap Liabilities
Liabilities
33518000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27539620
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27518895
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27471607
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27425447
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
358483000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
354752000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291109000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-249108000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
67377000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92359000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
139165000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13218000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16246000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29349000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31166000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6898000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8306000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14293000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14610000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20116000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24552000
us-gaap Operating Expenses
OperatingExpenses
43642000
us-gaap Operating Expenses
OperatingExpenses
45776000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20116000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24552000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43642000
us-gaap Operating Income Loss
OperatingIncomeLoss
-45776000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
761000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-61000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1641000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-190000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
761000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-61000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1641000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-190000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19355000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19355000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24613000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24613000
us-gaap Net Income Loss
NetIncomeLoss
-42001000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42001000
us-gaap Net Income Loss
NetIncomeLoss
-45966000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45966000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.90
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.68
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27468668
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27468668
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27384614
CY2022Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27384614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27451058
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27451058
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27376043
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
27376043
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
105647000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22646000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
84792000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
140000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1800000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-19355000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
67377000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2029000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-21353000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166121000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2709000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-24613000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
144217000
us-gaap Profit Loss
ProfitLoss
-42001000
us-gaap Profit Loss
ProfitLoss
-45966000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
991000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
885000
xlo Noncash Interest Expense
NoncashInterestExpense
118000
xlo Noncash Interest Expense
NoncashInterestExpense
106000
us-gaap Share Based Compensation
ShareBasedCompensation
3591000
us-gaap Share Based Compensation
ShareBasedCompensation
4738000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-2000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1069000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-857000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-221000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-188000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2167000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1217000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3204000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3204000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-444000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-386000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41824000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37591000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
486000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1025000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-486000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1025000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2778000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
42000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
140000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2680000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-26000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-44990000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38642000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
121947000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76957000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160964000
us-gaap Interest Paid Net
InterestPaidNet
332000
us-gaap Interest Paid Net
InterestPaidNet
240000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
154000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75383000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159410000
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
1574000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
1554000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76957000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160964000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-291100000
us-gaap Net Income Loss
NetIncomeLoss
-42000000.0
us-gaap Net Income Loss
NetIncomeLoss
-46000000.0
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75400000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Concentrations of Credit Risk </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are generally insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. Substantially all of the Company’s cash and cash equivalents are FDIC insured, including funds held through an insured cash sweep program. The Company has not experienced any losses in its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p>
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12080000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11673000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5282000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4418000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6798000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7255000
us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
800000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3105000
CY2022Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3178000
CY2023Q2 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
2774000
CY2022Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5413000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1032000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1536000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
200000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7140000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2023Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10233755
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8653472
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1800000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2709000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3591000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4738000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4960553
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.04
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
89000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1677205
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.71
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
324
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
662194
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.35
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5975240
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M28D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2410413
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M9D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
31000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.96
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.56
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6061584
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5263415

Files In Submission

Name View Source Status
0001558370-23-014711-index-headers.html Edgar Link pending
0001558370-23-014711-index.html Edgar Link pending
0001558370-23-014711.txt Edgar Link pending
0001558370-23-014711-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20230630.xsd Edgar Link pending
xlo-20230630x10q.htm Edgar Link pending
xlo-20230630xex10d1.htm Edgar Link pending
xlo-20230630xex31d1.htm Edgar Link pending
xlo-20230630xex31d2.htm Edgar Link pending
xlo-20230630xex32d1.htm Edgar Link pending
xlo-20230630_cal.xml Edgar Link unprocessable
xlo-20230630_def.xml Edgar Link unprocessable
xlo-20230630_lab.xml Edgar Link unprocessable
xlo-20230630_pre.xml Edgar Link unprocessable
xlo-20230630x10q_htm.xml Edgar Link completed